Pulmonary Embolism in Antiphospholipid Syndrome (APS)—Where Are We and Where Are We Going?
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020895 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Mateusz Lucki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department and Clinic of Cardiology, University of Medical Sciences, 60-545 Poznań, Poland. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Pulmonary Embolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medical Science of Poznań.
Abstract (Originalsprache)
Pulmonary embolism (PE) is one of the most serious complications of antiphospholipid syndrome (APS), a systemic autoimmune disorder defined by thrombotic events and persistent antiphospholipid antibodies (aPLA). PE occurs in 11–20% of patients and may constitute the initial clinical manifestation. Young and middle-aged women are most frequently affected, and triple-positive aPLA profiles markedly increase the risk of recurrence and long-term morbidity, including chronic thromboembolic pulmonary hypertension (CTEPH). This review article summarizes current evidence on the epidemiology, pathophysiology, diagnostic approach, and management of PE in APS. Key mechanisms include anti-β2-glycoprotein I-mediated endothelial and platelet activation, complement engagement, and neutrophil extracellular trap formation, resulting in immunothrombosis. Diagnostic pathways follow standard PE algorithms; however, chronically elevated D-dimer levels and lupus anticoagulant-related aPTT prolongation require careful interpretation and consideration. Long-term vitamin K antagonist therapy remains the standard of care, whereas direct oral anticoagulants are not recommended in high-risk APS. Future directions include improved risk stratification through detailed aPLA profiling and the use of emerging biomarkers, early screening for CTEPH, and the development of targeted therapies such as complement inhibition and anti-NETosis strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Clinic of Cardiology, University of Medical Sciences, 60-545 Poznań, Poland.
- Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
- Clinical Rehabilitation Laboratory, Department of Rehabilitation and Physiotherapy, University of Medical Sciences, 60-545 Poznań, Poland.
ORCID-Profile: Bogna Grygiel-Górniak, Ewa Lucka
Förderung
- University of Medical Science of Poznań
Zitieren
APA
Lucki, M., Grygiel-Górniak, B., Lucka, E., Lesiak, M., & Araszkiewicz, A. (2026). Pulmonary Embolism in Antiphospholipid Syndrome (APS)—Where Are We and Where Are We Going?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020895
Vancouver
Lucki M, Grygiel-Górniak B, Lucka E, Lesiak M, Araszkiewicz A. Pulmonary Embolism in Antiphospholipid Syndrome (APS)—Where Are We and Where Are We Going?. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020895
BibTeX
@article{Lucki2026,
author = {Lucki, Mateusz and Grygiel-Górniak, Bogna and Lucka, Ewa and Lesiak, Maciej and Araszkiewicz, Aleksander},
title = {Pulmonary Embolism in Antiphospholipid Syndrome (APS)—Where Are We and Where Are We Going?},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020895}
}
EUVIMED